BCM
RKDA icon

Bridgeway Capital Management’s Arcadia Biosciences RKDA Stock Holding History

Bridgeway Capital Management’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-50
Closed -$17K – 1439
2017
Q3 		$17K Hold
50
– – ﹤0.01% 1385
2017
Q2 		$18K Sell
50
-44
-47% -$24.5K ﹤0.01% 1404
2017
Q1 		$51K Hold
94
– – ﹤0.01% 1363
2016
Q4 		$69K Hold
94
– – ﹤0.01% 1371
2016
Q3 		$144K Hold
94
– – ﹤0.01% 1360
2016
Q2 		$194K Buy
+94
New +$157K ﹤0.01% 1309

Other funds holding RKDA

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Bridgeway Capital Management's RKDA Position: Q4 2017 in Review

Bridgeway Capital Management sold out of Arcadia Biosciences (RKDA) in Q4 2017, closing a stake of 50 shares — an estimated $17K sold.

Bridgeway Capital Management first reported a position in RKDA in Q2 2016 and held it in 6 quarters. The position peaked at $194K in Q2 2016. 8 funds tracked by Wall St. Rank hold RKDA as of Q4 2017.

  • Bridgeway Capital Management reported no remaining Arcadia Biosciences position as of Q4 2017 after selling out during the quarter.
  • Bridgeway Capital Management sold 50 Arcadia Biosciences shares in Q4 2017, an estimated $17K.
  • Bridgeway Capital Management first reported a position in Arcadia Biosciences in Q2 2016 and held it in 6 quarters.
  • Bridgeway Capital Management's Arcadia Biosciences position peaked at $194K in Q2 2016.
  • 8 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q4 2017.

Based on Bridgeway Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.